Brief: Immix Biopharma Announces Complete Response In Al Amyloidosis Clinical Trial
03/10/2023 14:29
Oct 3 (Reuters) - Immix Biopharma Inc IMMX.O :
* IMMIX BIOPHARMA ANNOUNCES COMPLETE RESPONSE IN 9TH
RELAPSED/REFRACTORY AL AMYLOIDOSIS PATIENT IN NXC-201 CLINICAL
TRIAL AT IMS 20TH ANNUAL MEETING
* IMMIX BIOPHARMA INC - PLANS TO SUBMIT A BLA FOR FDA
APPROVAL IN
AL AMYLOIDOSIS ONCE 40 PATIENTS ARE TREATED WITH NXC-201
* IMMIX BIOPHARMA INC - EXPECTED PRIMARY ENDPOINT FOR
NXC-201 IN
RELAPSED/REFRACTORY AL AMYLOIDOSIS IS OVERALL RESPONSE RATE
Source text for Eikon: ID:nGNE90NV0z
Further company coverage: IMMX.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Immix Biopharma
See all newsBrief: Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Brief: Immix Biopharma Announces Pricing Of $125 Million Underwritten Offering Of Common Stock
Brief: Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate
Immix Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary